Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 3%, and the phase III clinical study CREDIT-5 for the treatment of hyperlipidemia reached the main end

The Zhitong Finance App learned that Cinda Biotech (01801) rose by more than 3%. As of press release, it had risen 1.93% to HK$19.01, with a turnover of HK$1,226 billion.

^{According to news, on November 9, according to Cinda Biotech's official WeChat, the company announced today that its self-developed recombinant all-human anti-proprotein-converting enzyme subtilolysin 9 (PCSK9) monoclonal antibody Cinpirac® (tolecimab injection) carried out in Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia has reached the end of the 12th week of the main study.} In this study, the first-line monotherapy with Cinpirac ^® (tolecimab injection) showed significant lipid-lowering efficacy, and was safe and well tolerated.

Cipilac ^{® is the first PCSK9 antibody drug to be marketed in China, and was officially included} in the national medical insurance catalogue on January 1, 2025. ^{The positive results of this phase III clinical study marks another milestone in the field of hyperlipidemia treatment. Cinda Biotech will submit a marketing license application for new indications to the State Drug Administration in the near future, which is expected to provide a more convenient first-line treatment option for people with hyperlipidemia in China.}